Medication Description: Buspirone
8- [4- [4- (2-Pyrimidinyl) -1-piperazinyl] butyl] -8-azaspiro- [4,5] decane-7,9-dione.
Synonyms: Buspar, Spitomin, Bespar, Buspar, Spitomin
It differs from benzodiazepine tranquilizers by selective anxiolytic (anti-anxiety) action, does not possess anticonvulsant and miorealaxant properties, causes a less pronounced sedative effect.
The mechanism of action is not well understood.
When ingestion, it is quickly and completely absorbed, although the bioavailability is only 4%, Сmax - 40-90 minutes, T1 / 2 - 2-3 hours; subjected to intense biotransformation in the liver with the formation of the active metabolite (1-pyrimidinyl piperazine).
It is used primarily for the treatment of anxiety.
Assign inside, starting with 0.005 g (5 mg) 2-3 times a day, gradually increase the dose by 0.005 g (5 mg) every 2-3 days until the desired effect is achieved. The maximum daily dose of 0.06 g (60 mg).
The drug is usually well tolerated. Dyspepsia, chest pains, depression, muscle weakness, dizziness, fever, anxiety and rarely blurring of vision, insomnia, hallucinations, etc. are possible.
The drug is contraindicated in severe violations of the liver and kidneys.
Buspirone is not recommended for children and adolescents under the age of 18 years (due to the lack of sufficient data).
Product form: tablets of 0.005 and 0.01 g (5 and 10 mg) (N. 10.60).